AI and stable funding environments are catalysts for biotech assets
As the funding market evolves, there is greater emphasis on companies having commercial plans and using AI for drug discovery.
As the funding market evolves, there is greater emphasis on companies having commercial plans and using AI for drug discovery.
What's Your Reaction?
